Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA 2022-10-18 20:50
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline 2022-08-24 20:50
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology 2022-08-18 20:50
CARsgen Appoints Dr. Hua Jiang as Executive Director 2022-08-02 20:50
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 2022-06-06 20:50
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers 2022-05-10 20:50
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer 2022-04-07 23:42
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China 2022-03-23 20:50
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies 2022-03-23 20:50
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China 2022-03-03 21:50
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation 2022-01-17 21:50
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA 2022-01-10 21:50
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting 2021-12-13 20:00
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041 2021-11-22 20:00
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA 2021-11-15 22:10
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO 2021-09-20 08:24
CARsgen Therapeutics officially listing on HKEX 2021-06-19 02:57
1 2